Unaudited Financial Results for the Quarter and Half year ended 30.09.2025.

Net loss reportedRevenue declinedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹30.42

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-3.6% vs market

Pharmaceuticals peers, median of 157sector+0.1%-3.1% vs sector

On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0+0.6-3.6+0.1-3.1

Next day

-3.0-0.2-2.8-0.7-2.4

-4.8-0.4-4.4-1.1-3.7

-7.4-0.7-6.7-0.9-6.5

-12.0-2.2-9.7-1.9-10.0

-16.3-2.8-13.5-3.1-13.2

-16.5-1.4-15.1-2.1-14.4

15d

-2.4-7.0+4.6-4.8+2.4

-3.1-6.1+3.0-5.2+2.1

-21.4-9.2-12.2-7.6-13.9

-17.8-6.8-11.0-9.5-8.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ANG Lifesciences India posted standalone Q2 FY26 revenue of about ₹2,453 lakhs, down roughly 24% from around ₹3,216 lakhs in Q2 FY25, marking a sharp year-on-year decline. The company reported a Q2 FY26 standalone loss of approximately ₹103 lakhs, wider than the ~₹67 lakh loss in Q2 FY25. For H1 FY26, revenue was broadly flat at ~₹5,088 lakhs (vs ~₹5,006 lakhs in H1 FY25), while the half-year loss narrowed to about ₹164 lakhs from ~₹442 lakhs previously. Statutory auditor Khurana Sharma & Co. issued an unmodified review opinion on both standalone and consolidated results. The Board also approved the appointment of M/s Shreya Sahu & Associates as cost auditor for FY25-26, and cash and equivalents declined from ₹24.30 lakhs to ₹6.82 lakhs over the half-year, signalling weak liquidity.

Likely market impact

The steep quarterly revenue drop, persistent losses, and shrinking cash buffer point to ongoing financial stress that could weigh on the stock in the near term, although the narrower half-year loss offers a small positive signal. Shareholders should watch for further deterioration in revenue and cash generation.